- CA$17.62m
- CA$15.02m
- CA$9.63m
Brief: Ceapro Inc Reports Q1 Results
Brief: Ceapro Inc. Reports Fourth Quarter And Full Year 2020 Financial Results
Ceapro Inc: Rises after quarterly sales jump 20%
Brief: Ceapro Inc Reports 2020 Q3 And Nine-Month Financial Results And Operational Highlights
Brief: Ceapro Reports Qtrly Earnings Per Share C$0.01
Brief: Ceapro Inc Provides Update On Development Of An Inhalable Therapeutic For Covid-19
Brief: Ceapro Publishes Positive Results For A PGX Processed Drug Delivery System For Accelerated Burn Wound Healing
Brief: Ceapro Inc. Reports 2020 First Quarter Financial Results And Highlights
Brief: Ceapro Inc. Expands Collaborative Research Program With Mcmaster University To Develop Inhalable Therapeutic For Covid-19
Brief: Ceapro Q4 Sales C$3.721 Million
Brief: Ceapro Q4 Sales C$3.72 Mln
Brief: Ceapro Receives Research License From Health Canada Controlled Substances And Cannabis Branch
Brief: Ceapro Gains Approval From Health Canada For Protocol Expansion Of Current Clinical Study Assessing Beta Glucan As A Cholesterol-Lowering Agent
Brief: Ceapro Q3 Sales C$2.908 Million
Brief: Ceapro Inc Reports Qtrly Loss Per Share $0.01
Brief: Ceapro Presents Positive Results From Avenanthramides Study
Brief: Ceapro Commences Patient Enrollment In First-In-Human Clinical Study Assessing Beta Glucan As A Cholesterol-Lowering Agent
Brief: Ceapro Inc Reports Qtrly Loss Per Share $0.01
Brief: Ceapro Posts Positive Key Findings From Three Oral Presentations